Trials / Unknown
UnknownNCT04459676
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Angion Biomedica Corp · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standard of Care (SOC) + ANG-3777 | Standard of Care (SOC) + ANG-3777 |
| DRUG | Standard Of Care (SOC) + Placebo | Standard Of Care + Placebo |
Timeline
- Start date
- 2020-07-31
- Primary completion
- 2021-04-30
- Completion
- 2021-04-30
- First posted
- 2020-07-07
- Last updated
- 2021-04-15
Locations
10 sites across 1 country: Brazil
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04459676. Inclusion in this directory is not an endorsement.